Chemically synthesized cinobufagin suppresses nasopharyngeal carcinoma metastasis by inducing ENKUR to stabilize p53 expression. (10th April 2022)

• Record Type: Journal Article
• Authors: Hou, Rentao; Liu, Xiong; Yang, Huiling; Deng, Shuting; Cheng, Chao; Liu, Jiahao; Li, Yonghao; Zhang, Yewei; Jiang, Jingwen; Zhu, Zhibo; Su, Yun; Wu, Liyang; Xie, Yingying; Li, Xiaoning; Li, Wenmin; Liu, Zhen; Fang, Weiyi
• Is Part Of: Cancer letters. Volume 531(2022)
• Page Start: 57
• Page End: 70
• Publication Date: 2022-04-10
• Subjects: Cancer cell metastasis -- Cinobufagin -- ENKUR -- P53 -- Nasopharyngeal carcinoma; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.01.025
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Clinically, the metastasis of tumor cells is the key factor of death in patients with cancer. In this study, we used a model of metastatic nasopharyngeal carcinoma (NPC) to explore the effects of a new chemical, cinobufagin (CB), combined with cisplatin (DDP). We observed that chemically synthesized CB strongly decreased the metastasis of NPC. Furthermore, a better therapeutic effect was shown when CB was combined with DDP. Molecular analysis revealed that CB induced ENKUR expression by deregulating the PI3K/AKT pathway and suppressing c-Jun, an oncogenic transcriptional factor that binds to the ENKUR promoter and negatively modulated its expression in NPC. ENKUR as a tumor suppressor binds to MYH9 and decreases its expression by recruiting β-catenin via its enkurin domain to prevent its nuclear accumulation, which therefore suppresses c-Jun-induced MYH9 expression. Subsequently, downregulated MYH9 reduces the enlistment of E3 ligase UBE3A and thus decreases the UBE3A-mediated ubiquitination degradation of p53, a key tumor suppressor that decreases epithelial-mesenchymal transition (EMT). Clinical sample analysis demonstrated that the ENKUR expression level was significantly reduced in NPC tissues. Its decreased expression substantially promoted clinical progression and reflected poor prognosis for patients with NPC. This study demonstrated that CB induced ENKUR to repress the β-catenin/c-Jun/MYH9 signal and thus decreased UBE3A-mediated p53 ubiquitination degradation. As a result, the EMT signal was inactivated to suppress NPC metastasis. Highlights: ENKUR reduces NPC metastasis via inactivating β-catenin/c-Jun/MYH9 to decrease UBE3A-mediated p53 ubiquitination degradation. Chemical small molecule cinobufagin suppresses NPC metastasis by inducing ENKUR to modulate β-catenin/c-Jun/MYH9/p53 signal.